| Literature DB >> 36042614 |
Lin Dong1, Feng Xiaoli2, Lu Ya2, Wu Dan1, Hu Jingwen3, Liu Xun4, Chen Shujin2, Zhou Zhijun1, Zhang Tian1, Luo Hao1, Yi Chuanlang1, Chen Guangrong5, Wang Xiaodong6, Luo Gewen2, Zhang Yichi7, Cao Pei1, Liu Yang1, Wang Youliang8.
Abstract
BACKGROUND: To understand the long-term oncologic outcomes of open radical cystectomy (ORC) versus laparoscopic radical cystectomy (LRC) versus robot-assisted radical cystectomy (RARC) for bladder cancer (BCa). Therefore, we performed the conventional meta-analysis and network meta-analysis to evaluate the long-term oncologic outcomes of ORC, LRC, and RARC for BCa.Entities:
Mesh:
Year: 2022 PMID: 36042614 PMCID: PMC9410639 DOI: 10.1097/MD.0000000000030291
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Figure 1.Flowchart for records selection process of the meta-analysis. (According to PRISMA template: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal. Pmed 1000097). BCa = bladder cancer, CSS = cancer specific survival, LRC = laparoscopic radical cystectomy, ORC = open radical cystectomy, OS = overall survival, PFS = recurrence-free survival, RARC = robot-assisted radical cystectomy.
The main characteristics of included studies.
| Author | Study design | Follow-up (yr) | Group | No. of participants | Age (yr) | ASA | BMI (kg/m2) | Male proportion (%) | Urinary diversion | Clinical stage | Pathological stage | NOS score (Max: 9) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aboumarzouk et al (2013) | Retrospective | 5 | LRC | 75 | 60 ± 7.68 | N/A | 27.45 ± 2.2 | 88 | Yes | T2-T4 | 6 | |
| ORC | 80 | 62 ± 8.6 | 27.49 ± 3.76 | 82.5 | ||||||||
| Akin et al (2013) | Prospective | 5 | LRC | 15 | 62.2 ± 8.1 | N/A | 25.0 ± 1.1 | N/A | Yes | T1-T2 | T1-T2 | 6 |
| ORC | 15 | 64.0 ± 11.9 | 25.1 ± 1.4 | |||||||||
| Celen et al (2018) | Retrospective | 5 | LRC | 35 | 61 (50–80) | 1–3 | 25.34 (20.09–38.46) | 88.6 | Yes | T3-T4 | T3-T4 | 6 |
| ORC | 39 | 67 (48–91) | 26.81 (17.31–35.03) | 76.9 | ||||||||
| Esquinas et al (2018) | Prospective | 5 | LRC | 86 | 67,9 ± 9,9 | 2.3 ± 0.64 | N/A | N/A | Yes | T1-T4 | T1-T4 | 6 |
| ORC | 70 | 65,7 ± 8,65 | 2.1 ± 0.58 | |||||||||
| Faraj et al (2019) | Retrospective | 5 | RARC | 203 | 73.0 (67.0–78.0) | 3 (2–3) | 27.4 (25.0–30.6) | 82.3 | N/A | Tis-T4 | T2-T4 | 8 |
| ORC | 278 | 71 (65.0–77.0) | 28.1 (24.3–31.8) | 82 | ||||||||
| Gandaglia et al (2016) | Retrospective | 5 | RARC | 138 | 70.0 (60.7–77.0) | 1–4 | 26.1 (22.9–28.6) | 83.3 | Yes | T1-T4 | Tis-T4 | 8 |
| ORC | 230 | 70.9 (63.1–77.5) | 26.0 (23.5–29.0) | 83.5 | ||||||||
| Huang et al (2021) | Retrospective | 5 | LRC | 185 | 64 (58–72) | 1–4 | 24.31 (22.05–26.26) | 89.9 | Yes | Ta-T4 | Ta-T4 | 7 |
| ORC | 185 | 66 (59–71) | 1–3 | 24.22 (22.15–26.45) | 88 | |||||||
| Bochner BH et al (2018) | RCT | 5 | RARC | 60 | 66 (60–71) | ≥2 | N/A | 85 | Yes | T1-T4 | T1-T4 | |
| ORC | 58 | 65 (58–69) | 72 | |||||||||
| Khan et al (2019) | RCT | 5 | RARC | 20 | 68 (65–74) | 1–3 | 27.50 (24.00–31.00) | 85 | Yes | T0-Tis, T3-T4 | ||
| LRC | 19 | 71 (63–75) | 26.00 (24.00–27.59) | 79 | T0-T3 | |||||||
| ORC | 20 | 68 (58–74) | 26.99 (23.76–30.44) | 90 | T0-T4 | |||||||
| Lin et al (2014) | RCT | 5 | LRC | 26 | 63.2 ± 9.1 | 2–3 | 22.0 ± 2.7 | 91.4 | N/A | T1-T3 | T1-T4 | |
| ORC | 21 | 63.6 ± 8.9 | 22.9 ± 3.1 |
ASA = American Society of Anesthesiologist, BMI = body mass index, LRC = laparoscopic radical cystectomy, N/A = not available, NOS score = Newcastle-Ottawa Scale score, ORC = open radical cystectomy, RARC = robot-assisted radical cystectomy.
The efficacy of 3 surgical methods according to the network meta-analysis using odds ratios (ORs) and corresponding 95% credible intervals (CrIs).
| Consistent model | ||
|---|---|---|
| 5-year overall survival rate | ||
| LRC | 0.88 (0.57, 1.32) | 0.96 (0.50, 1.87) |
| 1.14 (0.76, 1.76) | ORC | 1.09 (0.67, 1.88) |
| 1.04 (0.53, 1.98) | 0.92 (0.53, 1.49) | RARC |
| 5-year cancer specific survival rate | ||
| LRC | 0.82 (0.37, 1.84) | 0.75 (0.31, 1.86) |
| 1.22 (0.54, 2.69) | ORC | 0.92 (0.53, 1.54) |
| 1.33 (0.54, 3.19) | 1.08 (0.65, 1.88) | RARC |
| 5-year recurrence free survival rate | ||
| LRC | 0.69 (0.35, 1.36) | 0.61 (0.22, 1.68) |
| 1.46 (0.74, 2.89) | ORC | 0.90 (0.41, 2.00) |
| 1.64 (0.59, 4.54) | 1.11 (0.50, 2.45) | RARC |
*LRC = laparoscopic radical cystectomy, ORC = open radical cystectomy, RARC = robot-assisted radical cystectomy.
Figure 2.The rank probability of the 3 surgical approaches for BCa included in this meta-analysis: (a) 5-year OS rate. (b) 5-year CSS rate. (c) 5-year RFS rate. BCa = bladder cancer, CSS = cancer specific survival, OS = overall survival, PFS = recurrence free survival.